CN101978965A - Use of medicine in treating diabetes - Google Patents
Use of medicine in treating diabetes Download PDFInfo
- Publication number
- CN101978965A CN101978965A CN 201010541451 CN201010541451A CN101978965A CN 101978965 A CN101978965 A CN 101978965A CN 201010541451 CN201010541451 CN 201010541451 CN 201010541451 A CN201010541451 A CN 201010541451A CN 101978965 A CN101978965 A CN 101978965A
- Authority
- CN
- China
- Prior art keywords
- inorganic acid
- acid salt
- medicine
- tetravalence
- pentavalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to use of medicine in preparation of a medicine for treating diabetes, which belongs to the field of chemical medicine. The invention provides use of the medicine in treating diabetes. The medicine is in the form of a percutaneously absorbable preparation; and the medicine contains the following active ingredients of inorganic acid salt of tetravalence V. The medicine has lower cost compared with similar products, reduces the economic load of the patient; and the percutaneously absorbable preparation is convenient to use and does not bring pains to the patient, the patient can take the medicine independently and stop medication at any moment. Clinical studies show that the medicine has no significant side effects, significant effect of treating the diabetes and quick response.
Description
Technical field
The present invention relates to the purposes of a kind of medicine in the treatment diabetes, belong to the chemical medicine field.
Background technology
Cancer, cerebral thrombosis, diabetes, nervous headache and insomnia are comparatively complicated difficult and complicated illness, and the patient suffers untold misery, and has a strong impact on patient's quality of life.At present the above-mentioned disease of treatment mainly adopt operative treatment and or expectant treatment, but no matter operative treatment and or expectant treatment, except costing an arm and a leg, its cure rate is all on the low side, and some treatment means also can increase the weight of patient's misery.
Vanadium is one of trace element necessary in the human body, and vanadium is extremely low at the intravital content of people, and insufficient total amount is 1 milligram in the body, mainly is distributed in internal organs, positions such as liver, kidney, thyroid especially, and content is also higher in the osseous tissue.Vanadium only is 5% at the gastrointestinal absorbance, and its absorption site is mainly at upper digestive tract.About 95% vanadium combines and carries with transferrins with ionic condition in the blood, so vanadium and ferrum can interact in human body.Vanadium is a many-side in the intravital function of people, and the most approved vanadium lacks the research to goat and white mouse that performance comes from report in 1987, and the goat that vanadium lacks shows the abortion ratio increase and milk yield reduces.In the white mouse experiment, the vanadium shortage causes growth inhibited, and the reproduction function is weak, the ratio increase of thyroid weight and body weight and the variation of plasma thyroid hormones concentration.At present, still indeterminate for the research of human body vanadium deficiency disease.
Heyliger in 1985 etc. find that for the first time vanadate has blood sugar reducing function to the diabetes white mouse, thereafter a series of animal experiment studies of numerous scientists show, vanadium is all effective to insulin dependent diabetes mellitus (IDDM) (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM), and is particularly effective to serious insulin resistant type animal.Vanadium has the same effect of insulin in human body, promote lipogenesis, suppresses the effect of decomposing.Its effect is to suppress glycogen heteroplasia enzymatic activity, reduces glyconeogenesis, suppresses the activity of tyrosine phospholipase, and plays the effect of receptor in insulin conducted signal path, thereby reduces hyperglycemia.
But all be to adopt oral administration to the research of the blood sugar reducing function of diabetes at present, the relevant report of administration by percutaneous absorption treatment diabetes do not arranged, and do not adopt the report of the phosphate treatment diabetes of vanadium for vanadate.
Summary of the invention
Technical problem to be solved by this invention provides the purposes of a kind of medicine in the treatment diabetes.
The invention provides the purposes of a kind of medicine in the medicine of preparation treatment diabetes, wherein, the dosage form of described medicine is a transdermal formulation, and described medicine comprises the inorganic acid salt of following active component: tetravalence V.
Further, better for the drug effect that makes medicine, the active component of said medicine also comprises the pentavalent V salt of phosphoric acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, better for the drug effect that makes medicine, the active component of said medicine also comprises proper inorganic acid, and wherein, described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When the active component of medicine contained mineral acid, it was a solution dosage, and the consumption of mineral acid gets final product to guarantee that the rest activity composition dissolves fully.
Further, better for the drug effect that makes medicine, the active component of said medicine also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-3Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
The active component of said medicine can only be the inorganic acid salt of tetravalence V.
Further, the active component of said medicine can also be the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, the active component of said medicine can also be the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
Further, the active component of said medicine can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-3Doubly, the inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
Wherein, the inorganic acid salt of the V of said medicine is preferably the V salt of sulfate, chlorate or phosphoric acid.
Wherein, the inorganic acid salt of above-mentioned tetravalence V is: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The inorganic acid salt of above-mentioned pentavalent V is VOCl
3Or (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Said medicine can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Wherein, above-mentioned transdermal formulation is preferably: patch, varnish, liniment, aerosol, unguentum or lotion.
The cost that medicine of the present invention is compared commercially available similar medicine is obviously lower, alleviated patient's financial burden, and transdermal formulation is easy to use, can not increase misery to the patient, and independently medication of patient also can be discontinued medication at any time.Show through clinical research, use medicine of the present invention not see that obvious toxic and side effects is arranged, treatment diabetes effect is remarkable, and drug effect is fast.The present invention has vast market prospect for treatment of diabetes provides a kind of new selection.
The specific embodiment
The invention provides the purposes of a kind of medicine in the medicine of preparation treatment diabetes, wherein, the dosage form of described medicine is a transdermal formulation, and described medicine comprises the inorganic acid salt of following active component: tetravalence V.
Further, better for the drug effect that makes medicine, the active component of said medicine also comprises the pentavalent V salt of phosphoric acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, better for the drug effect that makes medicine, the active component of said medicine also comprises proper inorganic acid, and wherein, described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When the active component of medicine contained mineral acid, it was a solution dosage, and the consumption of mineral acid gets final product to guarantee that the rest activity composition dissolves fully.
Further, better for the drug effect that makes medicine, the active component of said medicine also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10-6～10-3 doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
The active component of said medicine can only be the inorganic acid salt of tetravalence V.
Further, the active component of said medicine can also be the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, the active component of said medicine can also be the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
Further, the active component of said medicine can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10-6～10-3 doubly, the inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
Wherein, the inorganic acid salt of the V of said medicine is preferably the V salt of sulfate, chlorate or phosphoric acid.
Wherein, the inorganic acid salt of above-mentioned tetravalence V is: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The inorganic acid salt of above-mentioned pentavalent V is VOCl
3Or (VO
2)
2(SO
4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Said medicine can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Wherein, above-mentioned transdermal formulation is preferably: patch, varnish, liniment, aerosol, unguentum or lotion.
Medicine of the present invention is a transdermal formulation, administration by percutaneous absorption can be avoided contingent first pass effect of hepar of oral administration and gastrointestinal deactivation, reduce the side effect of gastrointestinal administration, prove through clinical research, medicine administration by percutaneous absorption treatment diabetes of the present invention, non-evident effect produces, and the patient can be according to self individual variation, regulate dosage, also can discontinue medication at any time.
When the dosage form of said medicine is lotion, when using, the patient medicine of the present invention can be added suitable quantity of water, and make the pH value of solution reach the acceptable faintly acid scope of human body, soak then or the scouring use, get final product about general soak time 10min, during immersion, soak every day 2～6 times.
Below in conjunction with embodiment the specific embodiment of the present invention is further described, does not therefore limit the present invention among the described scope of embodiments.
The preparation of embodiment 1 medicine
Molar concentration compounding pharmaceutical according to table 1.
The set of dispense of table 1 medicine of the present invention is than (mol/L)
Pharmaceutical dosage form is a lotion, and adding water during use, to be mixed with pH value be to soak behind 5.5 the solution or clean and use, and soak time is about 10min.
Test example 1 adopts drug treatment of diabetic of the present invention
Patient king xx, man, 65 years old.
Xerostomia appearred in 2007, polyuria polydipsia symptom.Through hospital diagnosis is diabetes, and fasting glucose is more than 11, and 2h blood glucose 25.6 after the meal.Recuperate under medical treatment into washing liquid with medicine of the present invention (embodiment 1, numbering 1), 4 foot bath about each 10min, treats and were checked to hospital after 3 months every day, and the result is: fasting glucose 5.33, uric acid 306, blood urea nitrogen 4.01, and equal range of normal value, blood fat, blood pressure are normal.
Test example 2 adopts drug treatment of diabetic of the present invention
Patient Lee xx, man, 50 years old.
Occur weak symptom at the beginning of 2008, obvious with two lower limb especially, two just transfer dimly red tongue, thin fur, stringy and thready pulse.Through hospital diagnosis is diabetes, and fasting glucose is more than 9.In JIUYUE, 2008 is recuperated under medical treatment into washing liquid with medicine of the present invention (embodiment 1, numbering 2), every day 3 foot bath, about each 10min.After medication January, thirsty, weak symptom obviously alleviates, and through examination in hospital: fasting glucose is stabilized in below 6, and two hours after the meal below 10.8.
Test example 3 adopts drug treatment of diabetic of the present invention
The patient opens * *, woman, 57 years old.
Suffered from diabetes in 2008, fasting glucose 9.6, two hours 20.2 after the meal, and the blood fat height, with insomnia.
Recuperate under medical treatment into washing liquid with medicine of the present invention (embodiment 1, numbering 8), every day 3 foot bath, about each 10min.Prolong the length of one's sleep after February, and the insomnia situation is clearly better, and fasting glucose reaches below 5.8.
From test example 1～3 as can be seen, medicine of the present invention can effectively be treated diabetes.
Claims (11)
1. the medicine purposes in the medicine of preparation treatment diabetes, wherein, the dosage form of described medicine is a transdermal formulation, described medicine comprises the inorganic acid salt of following active component: tetravalence V.
2. purposes according to claim 1, the active component that it is characterized in that described medicine also comprises the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
3. purposes according to claim 1 and 2 is characterized in that: the active component of described medicine also comprises proper inorganic acid, and wherein, described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
4. according to each described purposes of claim 1～3, it is characterized in that: the active component of described medicine also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10
-6～10
-3Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
5. purposes according to claim 1, the active component that it is characterized in that described medicine is the inorganic acid salt of tetravalence V.
6. purposes according to claim 1, the active component that it is characterized in that described medicine are the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
7. purposes according to claim 1, the active component that it is characterized in that described medicine are the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
8. purposes according to claim 1, the active component that it is characterized in that described medicine is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt content of described K, Na, Fe, Al, ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10-6～10-3 doubly, the inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
9. according to each described purposes of claim 1～8, it is characterized in that: the inorganic acid salt of the V of described medicine is the V salt of sulfate, chlorate or phosphoric acid.
10. purposes according to claim 9 is characterized in that: the inorganic acid salt of described tetravalence V is: VCl
4, VOCl
2, VOSO
4, (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The inorganic acid salt of described pentavalent V is VOCl
3Or (VO
2)
2(SO4)
3, VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
11. according to each described purposes of claim 1～10, it is characterized in that: described transdermal formulation is patch, varnish, liniment, aerosol, unguentum or lotion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105414518A CN101978965B (en) | 2010-06-24 | 2010-11-12 | Use of medicine in treating diabetes |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010208132.5 | 2010-06-24 | ||
| CN201010208132 | 2010-06-24 | ||
| CN201010216341 | 2010-07-02 | ||
| CN201010216341.4 | 2010-07-02 | ||
| CN2010105414518A CN101978965B (en) | 2010-06-24 | 2010-11-12 | Use of medicine in treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101978965A true CN101978965A (en) | 2011-02-23 |
| CN101978965B CN101978965B (en) | 2011-12-28 |
Family
ID=43450946
Family Applications (20)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102980383A Active CN101947238B (en) | 2010-06-24 | 2010-09-30 | Pharmaceutical composition for treating cancer and application thereof |
| CN2010102988277A Active CN101953846B (en) | 2010-06-24 | 2010-09-30 | Application of medicinal composition to preparing medicament for treating diabetes |
| CN2010105415845A Active CN101961347B (en) | 2010-06-24 | 2010-11-12 | Medicinal composition for treating cancer and use thereof |
| CN2010105414518A Active CN101978965B (en) | 2010-06-24 | 2010-11-12 | Use of medicine in treating diabetes |
| CN2011101250956A Pending CN102309505A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating organic sexual dysfunction |
| CN2011101255659A Pending CN102309517A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101254196A Pending CN102309514A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN2011101258093A Pending CN102309518A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN201110125808.9A Active CN102302511B (en) | 2010-06-24 | 2011-05-16 | Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction |
| CN2011101253672A Pending CN102309511A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101252951A Pending CN102309509A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
| CN 201110125426 Pending CN102309516A (en) | 2010-06-24 | 2011-05-16 | Drug composition and application thereof |
| CN2011101254209A Pending CN102309515A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101251677A Pending CN102309506A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101254105A Pending CN102309512A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN 201110125280 Pending CN102309508A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN2011101254177A Pending CN102309513A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN201110125431.7A Active CN102302510B (en) | 2010-06-24 | 2011-05-16 | Medicinal composition and application thereof |
| CN2011101253009A Pending CN102309510A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101251785A Pending CN102309507A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102980383A Active CN101947238B (en) | 2010-06-24 | 2010-09-30 | Pharmaceutical composition for treating cancer and application thereof |
| CN2010102988277A Active CN101953846B (en) | 2010-06-24 | 2010-09-30 | Application of medicinal composition to preparing medicament for treating diabetes |
| CN2010105415845A Active CN101961347B (en) | 2010-06-24 | 2010-11-12 | Medicinal composition for treating cancer and use thereof |
Family Applications After (16)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101250956A Pending CN102309505A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating organic sexual dysfunction |
| CN2011101255659A Pending CN102309517A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN2011101254196A Pending CN102309514A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN2011101258093A Pending CN102309518A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN201110125808.9A Active CN102302511B (en) | 2010-06-24 | 2011-05-16 | Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction |
| CN2011101253672A Pending CN102309511A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101252951A Pending CN102309509A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
| CN 201110125426 Pending CN102309516A (en) | 2010-06-24 | 2011-05-16 | Drug composition and application thereof |
| CN2011101254209A Pending CN102309515A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating insomnia |
| CN2011101251677A Pending CN102309506A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101254105A Pending CN102309512A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating rheumatism |
| CN 201110125280 Pending CN102309508A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating anemia |
| CN2011101254177A Pending CN102309513A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating hypertensive disease |
| CN201110125431.7A Active CN102302510B (en) | 2010-06-24 | 2011-05-16 | Medicinal composition and application thereof |
| CN2011101253009A Pending CN102309510A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of drugs for treating osteoporosis |
| CN2011101251785A Pending CN102309507A (en) | 2010-06-24 | 2011-05-16 | Application of drug composition in preparation of analgesic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (20) | CN101947238B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104398788A (en) * | 2014-11-25 | 2015-03-11 | 孙莉莉 | Traditional Chinese medicine electuary for treating insomnia and preparation method for traditional Chinese medicine electuary |
| CN106692546A (en) * | 2015-11-14 | 2017-05-24 | 张立 | Medicinal liquor for treating rheumatism and ostealgia |
| CN107375254A (en) * | 2017-08-30 | 2017-11-24 | 李炜 | A kind of external plaster and its application method for being used to treat diabetes |
| CN107485706A (en) * | 2017-09-01 | 2017-12-19 | 仲崇允 | A kind of Chinese medicine for treating breast cancer |
| CN114177196A (en) | 2020-09-14 | 2022-03-15 | 湖南方升泰医药科技有限公司 | Vanadium compounds for use in methods of treating pain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1278785A (en) * | 1997-09-11 | 2001-01-03 | 耶达研究及发展有限公司 | Vanadium complexes of monohydroxamates and pharmaceutical compositions comprising them |
| US20030077335A1 (en) * | 2000-11-03 | 2003-04-24 | Chronorx Llc | Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| CN1460472A (en) * | 2003-06-06 | 2003-12-10 | 乐益 | Biquanide vanadium complex plaster preparation for curing diabetes and its application |
| CN101033239A (en) * | 2007-01-31 | 2007-09-12 | 辽宁师范大学 | Preparation and structure of novel para-insulin pharmaceutical model compound |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843481A (en) * | 1994-01-18 | 1998-12-01 | Mount Sinai Hospital Corporation | Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof |
| CN1118243C (en) * | 1999-12-17 | 2003-08-20 | 王将克 | Nutritive soybean-pumpkin powder |
| CN1178946C (en) * | 2000-11-28 | 2004-12-08 | 昆明贵金属研究所 | Vanadium compound and its preparing process and usage |
| US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| CN1179659C (en) * | 2002-05-20 | 2004-12-15 | 郑军武 | Prep. of vanadium-enriched nutrient extender |
| CN1413727A (en) * | 2002-09-09 | 2003-04-30 | 凌一峰 | Composite medicine for radical curing AIDS |
| CN1187091C (en) * | 2002-09-24 | 2005-02-02 | 浙江大学 | Oral vanadium replenishing agent with bimetallic oxide as carrier and its prepn and usage |
| FI121915B (en) * | 2004-02-06 | 2011-06-15 | Neurofood Ab Oy | Composition for the treatment of psoriasis |
| US20070066682A1 (en) * | 2005-07-01 | 2007-03-22 | Exposito Miriam R | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus |
| WO2007043606A1 (en) * | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | Antidiabetic agent comprising anionic polyamino acid-metal complex |
| DE602007006641D1 (en) * | 2006-02-21 | 2010-07-01 | Astrum Therapeutics Pty Ltd | COMPOSITIONS FOR REDUCING THE BLOOD GLUCOSE MIRROR AND TREATING DIABETES |
| CN1846711A (en) * | 2006-04-25 | 2006-10-18 | 苟仕金 | Balanced solution with trace elements for extracorporeal culture of bezoar and its prepn process |
| CN101362684A (en) * | 2008-07-23 | 2009-02-11 | 郑德龙 | Solution containing vanadium oxalate and preparation method thereof |
-
2010
- 2010-09-30 CN CN2010102980383A patent/CN101947238B/en active Active
- 2010-09-30 CN CN2010102988277A patent/CN101953846B/en active Active
- 2010-11-12 CN CN2010105415845A patent/CN101961347B/en active Active
- 2010-11-12 CN CN2010105414518A patent/CN101978965B/en active Active
-
2011
- 2011-05-16 CN CN2011101250956A patent/CN102309505A/en active Pending
- 2011-05-16 CN CN2011101255659A patent/CN102309517A/en active Pending
- 2011-05-16 CN CN2011101254196A patent/CN102309514A/en active Pending
- 2011-05-16 CN CN2011101258093A patent/CN102309518A/en active Pending
- 2011-05-16 CN CN201110125808.9A patent/CN102302511B/en active Active
- 2011-05-16 CN CN2011101253672A patent/CN102309511A/en active Pending
- 2011-05-16 CN CN2011101252951A patent/CN102309509A/en active Pending
- 2011-05-16 CN CN 201110125426 patent/CN102309516A/en active Pending
- 2011-05-16 CN CN2011101254209A patent/CN102309515A/en active Pending
- 2011-05-16 CN CN2011101251677A patent/CN102309506A/en active Pending
- 2011-05-16 CN CN2011101254105A patent/CN102309512A/en active Pending
- 2011-05-16 CN CN 201110125280 patent/CN102309508A/en active Pending
- 2011-05-16 CN CN2011101254177A patent/CN102309513A/en active Pending
- 2011-05-16 CN CN201110125431.7A patent/CN102302510B/en active Active
- 2011-05-16 CN CN2011101253009A patent/CN102309510A/en active Pending
- 2011-05-16 CN CN2011101251785A patent/CN102309507A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1278785A (en) * | 1997-09-11 | 2001-01-03 | 耶达研究及发展有限公司 | Vanadium complexes of monohydroxamates and pharmaceutical compositions comprising them |
| US20030077335A1 (en) * | 2000-11-03 | 2003-04-24 | Chronorx Llc | Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| CN1460472A (en) * | 2003-06-06 | 2003-12-10 | 乐益 | Biquanide vanadium complex plaster preparation for curing diabetes and its application |
| CN101033239A (en) * | 2007-01-31 | 2007-09-12 | 辽宁师范大学 | Preparation and structure of novel para-insulin pharmaceutical model compound |
Non-Patent Citations (3)
| Title |
|---|
| 《化学进展》 20020731 杨晓改 等 钒化合物生物效应的化学基础和药用前景--金属药物研究的化学问题 全文 1-11 第14卷, 第4期 2 * |
| 《化学通报》 20010930 杨频 等 金属钒化合物作为胰岛素模拟物的研究进展 第553页，第557页 1-11 , 第9期 2 * |
| 《国外医学医学地理分册》 19960331 李洞 钒与糖尿病 第12-13页 1-11 第17卷, 第1期 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309513A (en) | 2012-01-11 |
| CN102309505A (en) | 2012-01-11 |
| CN101947238A (en) | 2011-01-19 |
| CN102302510A (en) | 2012-01-04 |
| CN102309516A (en) | 2012-01-11 |
| CN101961347B (en) | 2011-12-21 |
| CN102309518A (en) | 2012-01-11 |
| CN102309512A (en) | 2012-01-11 |
| CN102309509A (en) | 2012-01-11 |
| CN102309517A (en) | 2012-01-11 |
| CN101953846B (en) | 2011-12-28 |
| CN102309507A (en) | 2012-01-11 |
| CN102309510A (en) | 2012-01-11 |
| CN102302511B (en) | 2015-06-03 |
| CN102309508A (en) | 2012-01-11 |
| CN102309506A (en) | 2012-01-11 |
| CN101978965B (en) | 2011-12-28 |
| CN101961347A (en) | 2011-02-02 |
| CN102309514A (en) | 2012-01-11 |
| CN102302510B (en) | 2014-04-23 |
| CN102302511A (en) | 2012-01-04 |
| CN101953846A (en) | 2011-01-26 |
| CN101947238B (en) | 2011-12-21 |
| CN102309511A (en) | 2012-01-11 |
| CN102309515A (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101978965B (en) | Use of medicine in treating diabetes | |
| CN102370730B (en) | Self-heated traditional Chinese medicine (TCM) emplastrum for treating osteoarthritis | |
| CN107417556A (en) | L aspartase calciums and preparation method thereof | |
| CN101032512B (en) | Medicine composition for expanding blood volume and the preparing method thereof | |
| CN103356697B (en) | The oral liquid of a kind of stem cell medicine and preparation thereof | |
| CN101972273B (en) | Application of medicine in preparing medicines for treating diabetes mellitus | |
| Macalister | A new cell proliferant: its clinical application in the treatment of ulcers | |
| Arya et al. | Treating diabetes mellitus with vanadium salts–a future prospectus: a review | |
| CN102268098B (en) | Method for preparing yerbadetajo herb polyferose complex and application thereof | |
| CN102058617B (en) | Sodium heparin vitamin E gel and preparation method thereof | |
| CN102145010A (en) | Use of combination of potassium and magnesium for preparing medicine for preventing or treating gout | |
| CN108079035A (en) | A kind of hypoglycemic anti-inflammatory nutrient solution and preparation method thereof | |
| CN101953848A (en) | Medicament for treating cancer and application thereof | |
| CN107375614A (en) | Scar of dispelling patch and preparation method thereof | |
| WO2011160444A1 (en) | Pharmaceutical composition comprising vanadium and its use | |
| CN105878365A (en) | Anticancer drug and preparation method thereof | |
| CN104288229A (en) | Chinese medicinal oil solution for treating type 2 diabetes by transdermal absorption, and production process thereof | |
| CN102151285A (en) | Neutral calcium supplement preparation | |
| CN1457814A (en) | Medicine for curing tinea pedis | |
| PAIN et al. | wearying, aching kind, more connected with debility, and requiring stimulating | |
| CN101337006A (en) | Compound liniment for treating acne | |
| CN105078950A (en) | Composite preparation containing zinc, magnesium and calcium ions and preparing method of composite preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |